RCMNY
JAZZ icon

Rubric Capital Management (New York)’s Jazz Pharmaceuticals JAZZ Stock Holding History

Rubric Capital Management (New York)’s Portfolio JAZZ Stock Details JAZZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-616,617
Closed -$65.8M – 69
2024
Q2 		$65.8M Buy
+616,617
New +$67.8M 1.73% 20

Other funds holding JAZZ

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $46.4B AUM 27.74% 1-Year Est. Return
Pacer Advisors
Pacer Advisors Malvern, Pennsylvania $35.6B AUM 18.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Rubric Capital Management (New York)'s JAZZ Position: Q3 2024 in Review

Rubric Capital Management (New York) sold out of Jazz Pharmaceuticals (JAZZ) in Q3 2024, closing a stake of 616,617 shares — an estimated $65.8M sold.

Rubric Capital Management (New York) first reported a position in JAZZ in Q2 2024 and held it in 1 quarter. The position peaked at $65.8M in Q2 2024. 477 funds tracked by Wall St. Rank hold JAZZ as of Q3 2024.

  • Rubric Capital Management (New York) reported no remaining Jazz Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Rubric Capital Management (New York) sold 616,617 Jazz Pharmaceuticals shares in Q3 2024, an estimated $65.8M.
  • Rubric Capital Management (New York) first reported a position in Jazz Pharmaceuticals in Q2 2024 and held it in 1 quarter.
  • Rubric Capital Management (New York)'s Jazz Pharmaceuticals position peaked at $65.8M in Q2 2024.
  • 477 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q3 2024.

Based on Rubric Capital Management (New York)'s 13F filing for Q3 2024, filed 13 Nov 2024.